Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody therapy advances the company's immunology pipeline targeting autoimmune disorders. The Shanghai-listed biopharmaceutical firm specializes in novel antibody development with multiple candidates in preclinical and clinical stages. Approval enables Phase 1 human trials evaluating safety and pharmacokinetics. This milestone follows Genrix's strategic focus on innovative biologics addressing unmet medical needs across inflammatory and oncological indications. No trial timelines or specific indications were disclosed in the regulatory filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.